CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Kiora Pharmaceuticals, Inc. - KPRX CFD

    0.50
    1.96%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.06
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 0.51
    Open* 0.49
    1-Year Change* -86.61%
    Day's Range* 0.49 - 0.51
    52 wk Range 0.46-8.52
    Average Volume (10 days) 109.62K
    Average Volume (3 months) 6.57M
    Market Cap 4.31M
    P/E Ratio -100.00K
    Shares Outstanding 7.69M
    Revenue N/A
    EPS -4.44
    Dividend (Yield %) N/A
    Beta -0.27
    Next Earnings Date Mar 21, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 7, 2023 0.51 0.00 0.00% 0.51 0.51 0.49
    Dec 6, 2023 0.50 0.01 2.04% 0.49 0.51 0.48
    Dec 5, 2023 0.51 0.02 4.08% 0.49 0.51 0.49
    Dec 4, 2023 0.51 0.01 2.00% 0.50 0.51 0.49
    Dec 1, 2023 0.52 0.01 1.96% 0.51 0.52 0.51
    Nov 30, 2023 0.49 -0.02 -3.92% 0.51 0.51 0.47
    Nov 29, 2023 0.50 0.00 0.00% 0.50 0.52 0.49
    Nov 28, 2023 0.50 0.02 4.17% 0.48 0.50 0.48
    Nov 27, 2023 0.49 0.00 0.00% 0.49 0.49 0.49
    Nov 24, 2023 0.51 0.01 2.00% 0.50 0.51 0.50
    Nov 22, 2023 0.50 -0.04 -7.41% 0.54 0.54 0.50
    Nov 21, 2023 0.54 0.01 1.89% 0.53 0.54 0.53
    Nov 20, 2023 0.54 0.00 0.00% 0.54 0.55 0.53
    Nov 17, 2023 0.55 0.02 3.77% 0.53 0.55 0.53
    Nov 16, 2023 0.56 0.02 3.70% 0.54 0.56 0.54
    Nov 15, 2023 0.55 0.02 3.77% 0.53 0.55 0.49
    Nov 14, 2023 0.56 -0.01 -1.75% 0.57 0.57 0.54
    Nov 13, 2023 0.58 -0.01 -1.69% 0.59 0.59 0.57
    Nov 10, 2023 0.60 0.00 0.00% 0.60 0.61 0.60
    Nov 9, 2023 0.62 0.00 0.00% 0.62 0.64 0.59

    Kiora Pharmaceuticals, Inc. Events

    Time (UTC) Country Event
    Thursday, March 21, 2024

    Time (UTC)

    12:30

    Country

    US

    Event

    Q4 2023 Kiora Pharmaceuticals Inc Earnings Release
    Q4 2023 Kiora Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0.01206 2.686 1.65252
    Revenue 0 0.01206 2.686 1.65252
    Total Operating Expense 12.3095 13.9576 8.1111 9.79504 12.4972
    Selling/General/Admin. Expenses, Total 8.27799 5.32365 4.65877 4.40568 4.44146
    Research & Development 3.44893 5.35026 3.56605 5.38936 8.05576
    Operating Income -12.3095 -13.9576 -8.09904 -7.10904 -10.8447
    Interest Income (Expense), Net Non-Operating -1.39131 -0.00571 0.01915 0.10774 0.11932
    Other, Net
    Net Income Before Taxes -13.6966 -13.9633 -8.07989 -7.0013 -10.7254
    Net Income After Taxes -13.5836 -13.7707 -8.09194 -7.0967 -10.8114
    Minority Interest
    Net Income Before Extra. Items -13.5836 -13.7707 -8.09194 -7.0967 -10.8114
    Net Income -13.5836 -13.7707 -8.09194 -7.0967 -10.8114
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items -13.5836 -13.7707 -8.09194 -7.0967 -10.8114
    Income Available to Common Incl. Extra. Items -13.5836 -13.7707 -8.09194 -7.0967 -10.8114
    Diluted Net Income -13.5836 -13.7707 -8.09194 -7.0967 -10.8114
    Diluted Weighted Average Shares 0.7323 0.2411 0.1144 0.07953 0.05914
    Diluted EPS Excluding Extraordinary Items -18.5492 -57.1163 -70.7328 -89.238 -182.812
    Diluted Normalized EPS -18.5529 -46.9804 -71.379 -89.238 -182.812
    Unusual Expense (Income) 0 3.75962 -0.11372
    Other Operating Expenses, Total 0.58261 -0.47596
    Gain (Loss) on Sale of Assets 0.00421
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 2.63301 1.91667 2.635 3.70304 2.40205
    Selling/General/Admin. Expenses, Total 1.09729 1.26946 2.77796 2.03337 1.80188
    Research & Development 1.3921 0.43828 0.84162 1.33215 0.56723
    Other Operating Expenses, Total 0.14362 0.20893 -0.98458 0.33752 0.03294
    Operating Income -2.63301 -1.91667 -2.635 -3.70304 -2.40205
    Interest Income (Expense), Net Non-Operating 0.04509 0.03347 0.02448 -1.41724 0.00124
    Gain (Loss) on Sale of Assets 0 0 0 0
    Net Income Before Taxes -2.61381 -1.86854 -2.61146 -5.11934 -2.40081
    Net Income After Taxes -2.61381 -1.86854 -2.49845 -5.11934 -2.40081
    Net Income Before Extra. Items -2.61381 -1.86854 -2.49845 -5.11934 -2.40081
    Net Income -2.61381 -1.86854 -2.49845 -5.11934 -2.40081
    Income Available to Common Excl. Extra. Items -2.61381 -1.86854 -2.49845 -5.11934 -2.40081
    Income Available to Common Incl. Extra. Items -2.61381 -1.86854 -2.49845 -5.11934 -2.40081
    Diluted Net Income -2.61381 -1.86854 -2.49845 -5.11934 -2.40081
    Diluted Weighted Average Shares 3.28977 1.86347 1.4219 0.84853 0.32664
    Diluted EPS Excluding Extraordinary Items -0.79453 -1.00272 -1.75711 -6.03316 -7.34995
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.79453 -1.00272 -1.75711 -6.03316 -7.34995
    Unusual Expense (Income) 0 0 0
    Other, Net -0.02589 0.01467 -0.00094 0.00094
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 7.68067 8.99077 1.72622 4.32431 8.47843
    Cash and Short Term Investments 5.96456 7.85469 1.18568 3.77671 8.00424
    Cash & Equivalents 5.96456 7.85469 1.18568 3.77671 8.00424
    Total Receivables, Net 1.37304 0.52956 0.09098 0.00486 0.01844
    Prepaid Expenses 0.34307 0.60652 0.44957 0.45881 0.45576
    Total Assets 18.6783 20.1303 15.1576 10.1125 14.2806
    Property/Plant/Equipment, Total - Net 0.17217 0.28341 0.11449 0.01685 0.04352
    Intangibles, Net 10.7432 10.7682 9.73016 4.13106 4.15606
    Other Long Term Assets, Total 0.08226 0.08796 0.10207 0.1144 0.07671
    Total Current Liabilities 3.27236 1.60961 1.77233 1.4147 3.86438
    Accounts Payable 1.00826 0.16062 0.43476 0.21029 0.06365
    Accrued Expenses 1.75797 1.42003 1.33756 1.20441 1.11001
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.50614 0.02896 2.686
    Total Liabilities 7.27066 5.55126 8.15802 3.49006 5.34435
    Total Long Term Debt 0 0 0.27819 0 0
    Capital Lease Obligations 0
    Deferred Income Tax 0.68912 0.80213 0.72893 0.36536 0.26997
    Other Liabilities, Total 3.30918 3.13952 5.37858 1.71 1.21
    Total Equity 11.4076 14.5791 6.99954 6.62246 8.93627
    Redeemable Preferred Stock 0 0.00004 0.00004 0.00004
    Common Stock 0.01799 0.12664 0.05556 0.04078 0.43794
    Additional Paid-In Capital 146.035 135.418 115.284 106.689 101.514
    Retained Earnings (Accumulated Deficit) -134.463 -120.879 -108.339 -100.247 -93.1502
    Other Equity, Total -0.18274 -0.08643 -0.0008 0.13947 0.13433
    Total Liabilities & Shareholders’ Equity 18.6783 20.1303 15.1576 10.1125 14.2806
    Total Common Shares Outstanding 1.79647 0.3166 0.13891 0.10194 0.07299
    Total Preferred Shares Outstanding 0.00001 0.00001 0.00414 0.00409 0.00409
    Property/Plant/Equipment, Total - Gross 0.28949 0.39654 0.20747 0.09958 0.09958
    Accumulated Depreciation, Total -0.11732 -0.11313 -0.09297 -0.08273 -0.05606
    Goodwill, Net 0 3.48461 1.5259 1.5259
    Current Port. of LT Debt/Capital Leases 0 0.00472
    Other Current Assets, Total 0.08393
    Long Term Debt 0 0.27819
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 6.98298 9.02266 5.61798 7.68067 6.6242
    Cash and Short Term Investments 5.4005 7.95165 3.42607 5.96456 4.80162
    Cash & Equivalents 5.4005 7.95165 3.42607 5.96456 4.80162
    Total Receivables, Net 1.34309 0.80451 1.70297 1.37304 1.56258
    Prepaid Expenses 0.23939 0.2665 0.48895 0.34307 0.26001
    Total Assets 15.8964 19.8849 16.5276 18.6783 17.6623
    Property/Plant/Equipment, Total - Net 0.05734 0.0951 0.13585 0.17217 0.20665
    Property/Plant/Equipment, Total - Gross
    Accumulated Depreciation, Total
    Goodwill, Net
    Intangibles, Net 8.8201 10.7307 10.7369 10.7432 10.7494
    Other Long Term Assets, Total 0.03603 0.03652 0.03685 0.08226 0.08206
    Total Current Liabilities 2.10085 1.88322 2.15578 3.27236 2.9944
    Accounts Payable 0.12541 0.13132 0.58747 1.00826 0.74919
    Accrued Expenses 1.34026 1.39343 1.18513 1.75797 1.91586
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 7.79247 6.24259 6.37209 7.27066 7.14088
    Total Long Term Debt 0 0 0 0 0
    Long Term Debt
    Deferred Income Tax 0.68912 0.68912 0.68912 0.68912 0.80213
    Other Liabilities, Total 5.00251 3.67025 3.52719 3.30918 3.34435
    Total Equity 8.10397 13.6424 10.1555 11.4076 10.5214
    Redeemable Preferred Stock 0.00001 0.00001
    Common Stock 0.07692 0.06913 0.01921 0.01799 0.01079
    Additional Paid-In Capital 153.001 152.744 146.683 146.035 142.739
    Retained Earnings (Accumulated Deficit) -144.708 -138.945 -136.331 -134.463 -131.965
    Other Equity, Total -0.26617 -0.22586 -0.21541 -0.18274 -0.2634
    Total Liabilities & Shareholders’ Equity 15.8964 19.8849 16.5276 18.6783 17.6623
    Total Common Shares Outstanding 7.68924 6.91072 1.91927 1.79647 1.07905
    Total Preferred Shares Outstanding 0 0.00001 0.00001
    Other Current Liabilities, Total 0.63517 0.35846 0.38319 0.50614 0.32934
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -13.5836 -13.7707 -8.09194 -7.0967 -10.8114
    Cash From Operating Activities -10.4281 -10.6754 -7.31717 -8.15383 -10.8445
    Cash From Operating Activities 0.04161 0.0453 0.0334 0.05167 0.03848
    Non-Cash Items 2.55837 4.2784 1.05053 1.51449 0.87529
    Changes in Working Capital 0.66851 -1.0358 -0.32121 -2.7187 -1.0329
    Cash From Investing Activities 0.00638 -0.15702 -0.24444 0 -0.27
    Capital Expenditures 0 -0.06387 -0.02008 0 -0.27
    Other Investing Cash Flow Items, Total 0.00638 -0.09316 -0.22436
    Cash From Financing Activities 8.62092 17.5829 4.9975 3.92081 11.3048
    Financing Cash Flow Items -0.01563 -1.00481 -0.49869 -0.00261 0
    Issuance (Retirement) of Stock, Net 8.63655 18.8 5.218 3.92813 11.3146
    Foreign Exchange Effects -0.08504 -0.0815 -0.02693 0.0055 0.00792
    Net Change in Cash -1.88587 6.66901 -2.59104 -4.22753 0.19821
    Deferred Taxes -0.11301 -0.1926 0.01206 0.0954 0.08605
    Issuance (Retirement) of Debt, Net 0 -0.21228 0.27819 -0.00472 -0.00978
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -1.86854 -13.5836 -11.0852 -5.96583 -3.56501
    Cash From Operating Activities -3.06959 -10.4281 -8.29913 -5.33133 -2.83239
    Cash From Operating Activities 0.01008 0.04161 0.03132 0.02105 0.01077
    Non-Cash Items 0.37765 2.55837 2.55614 0.63704 0.4967
    Changes in Working Capital -1.58878 0.66851 0.19857 -0.02359 0.22515
    Cash From Investing Activities 0 0.00638 0.00638 0.00638 0.00638
    Capital Expenditures 0 0 0 0
    Cash From Financing Activities 0.51318 8.62092 5.37772 0 0
    Issuance (Retirement) of Stock, Net 0.51318 8.63655 5.37772 0 0
    Foreign Exchange Effects -0.02715 -0.08504 -0.134 -0.09753 0.03868
    Net Change in Cash -2.58356 -1.88587 -3.04904 -5.42248 -2.78734
    Issuance (Retirement) of Debt, Net 0 0
    Deferred Taxes -0.11301
    Other Investing Cash Flow Items, Total 0 0.00638 0.00638 0.00638 0.00638
    Financing Cash Flow Items -0.01563

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Kiora Pharmaceuticals, Inc. Company profile

    About Kiora Pharmaceuticals Inc

    Kiora Pharmaceuticals, Inc., formerly Eyegate Pharmaceuticals, Inc., is a clinical-stage pharmaceutical company. The Company is engaged in developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system. The Company's pipeline consists of three assets including KIO-101, KIO-301, and KIO-201 in early to late-stage development for both common and rare eye diseases. KIO-101, is a non-steroidal, immuno-modulatory and small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH). Its KIO-301, is a light-sensitive small molecule that acts as a reversible photoswitch, designed to restore the eyes' ability to perceive and interpret light in visually impaired patients. The Company's KIO-201, which is a form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve ocular surface integrity.

    Financial summary

    BRIEF: For the nine months ended 30 September 2021, Kiora Pharmaceuticals Inc revenues was not reported. Net loss increased 41% to $8M. Higher net loss reflects Research and Development Expense - Balan increase of 73% to $4.2M (expense), General and Administrative Expense - Bal increase of 26% to $3.5M (expense), Stock-based Compensation in SGA increase of 19% to $453K (expense).

    Industry: Pharmaceuticals (NEC)

    1371 East 2100 South
    Suite 200
    SALT LAKE CITY
    UTAH 84105
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    BTC/USD

    44,252.10 Price
    +2.010% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Oil - Crude

    71.41 Price
    +2.320% 1D Chg, %
    Long position overnight fee -0.0204%
    Short position overnight fee -0.0015%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    XRP/USD

    0.68 Price
    +4.560% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    US100

    16,080.90 Price
    +0.500% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading